Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Androgen deprivation therapy (ADT) is standard for advanced prostate cancer but often leads to castration-resistant prostate cancer (CRPC).
• The arylpiperazine derivative NAF19 shows potential against prostate cancer, but its mechanisms require elucidation.
• Understanding NAF19's action is crucial for developing new treatments for advanced prostate cancer.

Purpose of the Study:

• To evaluate the antitumor effects of NAF19 on various prostate cancer cell lines.
• To elucidate the molecular mechanisms underlying NAF19's action.
• To investigate NAF19's multi-target inhibition of AR/AR-Vs and survival pathways.

Main Methods:

• Prostate cancer cell lines were treated with NAF19; viability was assessed via CCK-8 assay.
• Gene expression (AR/AR-Vs, PSA, UBE2C), cell cycle, apoptosis markers (PARP, Bcl-2 family), and signaling proteins (AKT, ERK, S6) were analyzed.
• Migration, invasion, proliferation, and AR transcriptional activity were evaluated using functional assays.

Main Results:

• NAF19 inhibited growth in all tested prostate cancer cell lines.
• NAF19 suppressed AR/AR-Vs downstream gene expression and induced G1 cell cycle arrest.
• NAF19 promoted apoptosis, reduced anti-apoptotic proteins, and inhibited AKT, ERK, and S6 phosphorylation, suppressing migration, invasion, and proliferation.

Conclusions:

• NAF19 demonstrates multi-targeted antitumor activity against prostate cancer.
• NAF19 concurrently inhibits AR/AR-Vs signaling and activates apoptosis.
• NAF19 effectively suppresses prostate cancer cell migration, invasion, and proliferation.